Cyclerion Therapeutics, Inc. (CYCN)

Market Cap	38.31M
Revenue (ttm)	1.55M
Net Income (ttm)	-47.64M
Shares Out	43.49M
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,364
Open	0.876
Previous Close	0.9
Day's Range	0.86 - 0.905
52-Week Range	0.35 - 2.05
Beta	1.75
Analysts	Buy
Price Target	4.08 (+365.6%)
Earnings Date	Nov 8, 2022

About CYCN

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also ...

• Industry: Biotechnology
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: CYCN

Financial Performance

In 2021, CYCN's revenue was $3.94 million, an increase of 71.69% compared to the previous year's $2.30 million. Losses were -$51.65 million, -33.62% less than in 2020.

Analyst Forecast

According to 7 analysts, the average rating for CYCN stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 365.59% from the latest price.

Price Target

$4.08

(365.59% upside)

Analyst Consensus: Buy